Showing 1991-2000 of 5627 results for "".
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- CDC Endorses Use of Pfizer, BioNTech COVID-19 Vaccine in Teens as Young as 12https://modernod.com/news/cdc-endorses-use-of-pfizer-biontech-covid-19-vaccine-in-teens-as-young-as-12/2479204/An advisory panel of the US Centers for Disease Control and Prevention (CDC) on Wednesday voted 14-0, with one recusal, to endorse the FDA’s recent decision to extend use of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 to 12- to 15-year-olds, according to FirstWord. The recommendat
- FDA Authorizes Pfizer, BioNTech’s COVID-19 Vaccine for Younger Adolescentshttps://modernod.com/news/fda-authorizes-pfizer-biontechs-covid-19-vaccine-for-younger-adolescents/2479191/The FDA on Monday expanded the emergency-use authorization (EUA) for Pfizer and BioNTech’s vaccine BNT162b2 to include preventing COVID-19 in adolescents 12 through 15 years of age, according to a FirstWord report. The two-dose mRNA-based vaccine was initially granted an EUA in December for
- ProQR Therapeutics and Yarrow Biotechnology Announce Exclusive License and Discovery Collaboration for Undisclosed Ophthalmic Targethttps://modernod.com/news/proqr-therapeutics-and-yarrow-biotechnology-announce-exclusive-license-and-discovery-collaboration-for-undisclosed-ophthalmic-target/2479165/RTW Investments and ProQR Therapeutics announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is f
- Hoya Vision Care Releases Results of 3-Year MiYOSMART Spectacle Lens Follow-up Studyhttps://modernod.com/news/hoya-vision-care-releases-results-of-3-year-miyosmart-spectacle-lens-follow-up-study/2479124/Hoya Vision Care shared the results of a 3-year follow-up clinical study on its MiYOSMART spectacle lens with patented Defocus Incorporated Multiple Segments (D.I.M.S.) Technology after releasing the information at the recent European Academy of Optometry and Optics (EAOO) ’21 conference. T
- Market Scope: US Cataract Pharmaceuticals Evolve in Drug Deliveryhttps://modernod.com/news/market-scope-us-cataract-pharmaceuticals-evolve-in-drug-delivery/2479107/US cataract surgeons showed a preference for incremental improvement in drug delivery over revolutionary change in the first full year for three new corticosteroid products to manage inflammation and pain after cataract surgery, according to a Market Scope report. The products hit the mark
- HK Scientist Develops Retinal Scan Technology to Identify Early Childhood Autismhttps://modernod.com/news/hk-scientist-develops-retinal-scan-technology-to-identify-early-childhood-autism/2478987/A Hong Kong scientist has developed a method to use machine learning and artificial intelligence to scan retinas of children as young as six to detect early autism or the risk of autism and hopes to develop a commercial product this year, according to a Reuters
- Johnson & Johnson Vision Celebrates 20 Years of See More Campaign and Global Patient Story Searchhttps://modernod.com/news/johnson-johnson-vision-celebrates-20-years-of-see-more-campaign-and-global-patient-story-search/2478846/Johnson & Johnson Vision announced a month-long celebration of the 20th Anniversary of the Tecnis platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs are built. Twenty years ago, a team of researchers and innovators created Tecnis, setting
- Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Wet AMDhttps://modernod.com/news/prevent-blindness-and-bausch-lomb-to-launch-year-long-video-series-to-raise-awareness-of-wet-amd/2478818/Bausch + Lomb and Prevent Blindness, the nation’s oldest volunteer eye health non-profit organization, announced they are joining together for the sixth consecutive year during AMD Awareness Month to raise awareness of age-related macular degeneration (AMD). The two organizations will launch a ye
- Fewer New Cases of Intraocular Inflammation After First Year of Abicipar in AMD Patientshttps://modernod.com/news/fewer-new-cases-of-intraocular-inflammation-after-first-year-of-abicipar-in-amd-patients/2478703/Most cases of intraocular inflammation in patients with neovascular age-related macular degeneration (nAMD) who take AbbVie’s investigational drug abicipar pegol develop during the first year of treatment, according to a new report of two-year efficacy and safety results from a couple of pi